Atypical femoral fractures and bisphosphonate treatment: Experience in two large United Kingdom teaching hospitals

Journal of Bone and Joint Surgery - Series B

Volumn 94 B, Issue 3, 2012, Pages 385-390

  Thompson, R N ^a   Phillips, J R A ^b   McCauley, S H J ^a   Elliott, J R M ^a   Moran, C G ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BONE PAIN; BONE RADIOGRAPHY; FEMALE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; ENGLAND; FEMALE; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; MALE; NORTHERN IRELAND; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES;

EID: 84863396445     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.94B3.27999     Document Type: Article

References (24)

1. Neviaser AS, Lane JM, Lenart BA, Edobar-Osula F, Lorich DG. Low energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-350. (Pubitemid 351630250)
2. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010;7:161-168.
3. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fracture: a long term complication of alendronate therapy? Injury 2008;39:224-231.
4. Goddard MS, Reid KR, Johnston JC, Khanuja HS. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 2009;32:624-627.
5. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy. J Bone Joint Surg [Br] 2007;89-B:349-353. (Pubitemid 46563912)
6. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301. (Pubitemid 40463979)
7. No authors listed. National institute for health and clinical excellence: osteoporosis - primary prevention: guidance, 2008 (TA160). http://guidance. nice.org.uk/TA160/Guidance/pdf/English (date last accessed 2 November 2011).
8. No authors listed. National institute for health and clinical excellence: osteoporosis - secondary prevention including strontium ranelate: guidance, 2008 (TA161). http://guidance.nice.org.uk/TA161/Guidance/pdf/English (date last accessed 2 November 2011).
9. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307-312. (Pubitemid 43670914)
10. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997;12:1700-1707. (Pubitemid 27422371)
11. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-2294.
12. Burr DB. Is Bisphosphonate therapy a risk factor for subtrochanteric femoral fractures? J Am Acad Orthop Surg 2009;17:57-58.
13. Wiles M, Moran C, Sahota O, Moppett I. Nottingham Hip Fracture Score as a predictor of one year mortality in patients undergoing surgical repair of fractured neck of femur. Br J Anaesth 2011;106:501-504.
14. No authors listed. National Guideline Clearinghouse: a national clinical guideline: management of osteoporosis, 2003. http://www.guideline.gov/content. aspx?id=3876 (date last accessed 2 November 2011).
15. Aspenberg P. Bisphosphonate-induced fractures: nature strikes back? Acta Orthop 2008;79:459-460.
16. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009;122:14-21.
17. Black DM, Cummings SR, Karpf DB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541. (Pubitemid 26411651)
18. Imai K, Yamamoto S, Anamizu Y, Horiuchi T. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 2007;25:333-336. (Pubitemid 47283272)
19. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg [Br] 2010;92-B:679-686.
20. Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res 2009;24:1132-1134.
21. Sayed-Noor AS, Sjödén GO. Subtrochanteric displaced insufficiency fracture after long term alendronate therapy: a case report. Acta Orthop 2008;79:565-567.
22. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009;80:413-415.
23. Black DM, Schwartz AV, Ensrud KE. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Long-term extension (FLEX): a randomized trial. JAMA 2006;296:2927-2938. (Pubitemid 46021497)
24. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20:1291-1300. (Pubitemid 39120794)